A Study of Lactate Dehydrogenase (LDH) Levels and Other Biomarkers in Breast Cancer Patients Undergoing Chemotherapy
Baghdad Journal of Biochemistry and Applied Biological Sciences · 10.04.2026 · 7 (2) · 102-109
DOI: 10.47419/bjbabs.v7i2.451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Baghdad Journal of Biochemistry and Applied Biological Sciences, online erschienen am 10.04.2026. Verfasst von Abeer Erfan und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Breast cancer, after lung cancer, is the second leading cause of cancer-related deaths worldwide, making early diagnosis and continuous treatment crucial. This study evaluated the levels of serum lactate dehydrogenase (LDH) enzyme and other biochemical parameters in post-operative chemotherapy in Iraqi women diagnosed with breast cancer. This study highlights the potential use of LDH as a biomarker for monitoring treatment response, rather than being limited to its traditional diagnostic role.
Objective
To assess the prognostic value of serum LDH along with other biochemical markers, such as alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), electrolytes (Na⁺, K⁺, and Cl⁻), kidney functions (urea and creatinine), and prolactin hormone.
Methods
A cross-sectional study was conducted on 150 serum samples collected from 100 female patients diagnosed with breast cancer (after surgery and during chemotherapy) and 50 age matched healthy women, aged 26–60 years, as a control group. The samples were collected at Al-Amal National Hospital for Cancer Management, Medical City, Baghdad, Iraq, from July 2021 to October 2021. All biochemical parameters (LDH, ALP, ALT, AST, Na⁺, K⁺, Cl⁻, urea,\ creatinine, and prolactin) were measured in the hospital laboratory using standard automated biochemical analyzers and commercially available diagnostic kits.
Results
LDH activity was significantly elevated in breast cancer patients, highlighting its potential as an early prognostic marker for progression or recurrence of disease. Renal function tests (urea and creatinine) and liver enzymes (ALT and AST) were significantly higher in patients, compared to controls (P < 0.05). Electrolytes, specifically K⁺ and Cl⁻, were elevated (P < 0.05), while Na⁺ showed no significant difference (P > 0.05). Levels of ALP were not significantly different between patients and controls (P > 0.05). Level of prolactin hormone was also significantly higher in patients (P < 0.05) than in controls. These findings underscore LDH as a central prognostic marker, with other biochemical parameters providing supportive information on patient status.
Conclusion
Elevated serum LDH levels in breast cancer patients may serve as an early prognostic marker for progression or recurrence of disease, offering a practical tool for monitoring response to treatment.
Zitieren
APA
Erfan, A., Yousif, E., Alshanon, A., Bufaroosha, M., Amalia, H., Imran, Y., Hairunisa, N., & Alsayed, R. (2026). A Study of Lactate Dehydrogenase (LDH) Levels and Other Biomarkers in Breast Cancer Patients Undergoing Chemotherapy. Baghdad Journal of Biochemistry and Applied Biological Sciences, 7(2), 102-109. https://doi.org/10.47419/bjbabs.v7i2.451
Vancouver
Erfan A, Yousif E, Alshanon A, Bufaroosha M, Amalia H, Imran Y, et al. A Study of Lactate Dehydrogenase (LDH) Levels and Other Biomarkers in Breast Cancer Patients Undergoing Chemotherapy. Baghdad Journal of Biochemistry and Applied Biological Sciences. 2026;7(2):102-109. doi:10.47419/bjbabs.v7i2.451
BibTeX
@article{Erfan2026,
author = {Erfan, Abeer and Yousif, Emad and Alshanon, Ahmed and Bufaroosha, Muna and Amalia, Husnun and Imran, Yudhisman and Hairunisa, Nany and Alsayed, Raghda},
title = {A Study of Lactate Dehydrogenase (LDH) Levels and Other Biomarkers in Breast Cancer Patients Undergoing Chemotherapy},
journal = {Baghdad Journal of Biochemistry and Applied Biological Sciences},
year = {2026},
volume = {7},
number = {2},
pages = {102--109},
doi = {10.47419/bjbabs.v7i2.451}
}
EUVIMED